# 1. Financial Performance ## A. Key Figures * **Revenue:** **₹9,128 Cr** FY26 (+17.3%) · **₹2,365 Cr** Q4 (+17.8%) * **PAT:** **₹1,064 Cr** FY26 (+31.5%) · **₹271 Cr** Q4 (+44.2%) * **Operating EBITDA:** **₹2,085 Cr** FY26 (+31.3%) · **22.8%** FY26 Margin (+240 bps) * **Hospital Segment:** **₹7,773 Cr** FY26 Rev (+19.1%) · **22.2%** FY26 Margin (+170 bps) * **Leverage & Returns:** **1.09x** Net Debt/EBITDA · **₹1.00** Dividend per share ## B. Revenue & Profitability * **Hospital Dominance:** The hospital business remains the primary growth engine, now contributing the vast majority of consolidated top-line and EBITDA. * **Inorganic & Brownfield Contribution:** Quarterly performance was bolstered by the addition of **800 new beds** through strategic acquisitions and facility expansions. * **International Recovery:** Despite a recent quarterly dip, annual medical tourism revenue showed robust double-digit growth, maintaining a steady share of the hospital mix. * **Asset Turnaround:** The Manesar facility achieved a critical milestone by reaching EBITDA breakeven, transitioning from a prior-year loss to a positive contributor. ## C. Margin Expansion * **Operational Efficiency:** Margin accretion is driven by a broader base of high-performing assets, with **13 facilities** now operating above the 20% EBITDA threshold. * **Portfolio Optimization:** Profitability is trending upward as previously loss-making units in **Greater Noida and Ludhiana** begin contributing positively to the bottom line. * **Clinical Excellence:** Significant margin improvements at FEHI are attributed to the successful integration of new clinical talent and upgraded infrastructure. ## D. Debt & Capital Allocation * **Strategic Leverage:** Net debt increased slightly to support aggressive M&A and investments, though leverage remains conservative at just over **1x EBITDA**. * **Disciplined Capex:** Annual guidance is set at **₹900 Cr**, with a **60/40 split** between maintenance and growth initiatives to modernize medical infrastructure. * **Prudent Expansion:** Management signaled a commitment to non-dilutive growth, prioritizing the protection of existing market leadership over high-risk expansions. --- # 2. Hospital Operations & Capacity ## A. Key Figures * **Occupancy:** **68%** FY26 Group Average · **90-95%** FMRI · **55%** BG Road · **48%** Manesar * **Expansion Pipeline:** **~250 beds** FY26 added · **>400 beds** FY27 target · **1,800 beds** 4-year outlook ## B. Bed Additions & Brownfield Strategy * **Phased Capacity Activation:** Management is utilizing a phased rollout for new capacity, specifically at the new FMRI tower, to optimize cost management as occupancy ramps. * **Strategic Deferrals:** While **500-plus** beds are slated for next fiscal, approximately **300 beds** at Shalimar Bagh have been pushed to **FY29** due to regulatory delays. * **Margin Accretion:** Brownfield expansions in Noida and Faridabad have demonstrated rapid margin ramp-ups; similar economies of scale are expected from upcoming projects. * **Regional Discipline:** In Bangalore, **100 beds** are ready but withheld from commissioning until existing occupancy levels show sufficient improvement. ## C. Occupancy Trends & Market Mix * **International Business Headwinds:** A slowdown in international growth (decelerating to **11%** this quarter) has pressured occupancy at flagship units like FMRI and BG Road. * **Payer Mix Optimization:** Lower occupancy at the BG Road unit reflects a strategic pivot to prioritize high-margin TPA and cash business over government (CGHS) contracts. * **Geographic Diversification:** To counter international volatility, the company is broadening its patient sourcing with a renewed focus on the **African market**. * **Operational Synergies:** The Manesar facility is successfully serving as a satellite base for FMRI clinicians, expanding the operational footprint without cannibalizing the main unit. ## D. ARPOB Metrics & Unit Performance * **High-Value Clinical Mix:** Robust ARPOB growth at FMRI and FEHI highlights a shift toward complex cases and international patients, who command higher gross markups. * **Utilization Benchmarks:** With the Mulund facility reaching sustainable utilization levels, management has triggered planning for an additional tower to capture further demand. --- # 3. Diagnostic Segment Performance ## A. Key Figures * **Net Revenue (Agilus):** **₹1,355 Cr** FY26 (+8%) * **Gross Revenue (Agilus):** **₹1,527 Cr** FY26 (+8.5%) · **₹387 Cr** Q4 FY26 (+11.1%) * **Operating EBITDA Margin:** **23.2%** FY26 (vs 22% FY25) · **20.1%** Q4 FY26 (vs 23.4% Q4 FY25) * **Test Volumes:** **4.08 Cr** FY26 · **1 Cr** Q4 FY26 (+5%) ## B. Operational Performance & Mix * **Volume-Led Growth Strategy:** Revenue expansion is structurally driven by a **70/30 volume-to-value mix**, maintaining a balanced B2C to B2B revenue ratio of **52:48**. * **Network Scaling:** Aggressive footprint expansion achieved through the addition of **675 customer touchpoints** and **20 new laboratories**, including 10 hospital lab management sites. * **Quarterly Margin Compression:** Despite annual expansion, Q4 margins saw a year-on-year contraction, though absolute Q4 operating EBITDA reached **₹85 Cr**. ## C. Forward Outlook * **Targeted Profitability:** Management is guiding for improved EBITDA margins between **23% and 24%** in the upcoming fiscal year. * **Growth Acceleration:** Revenue momentum is expected to shift into **double digits**, improving upon the high single-digit growth recorded in the current period. --- # 4. Product & Specialty Mix ## A. Key Figures * **Focus Specialty Revenue:** **62%** of total hospital revenue (+18.9%) * **High-Acuity Volume Growth:** **66%** Robotic Surgeries · **19%** Radiation Therapy * **Preventive Health Contribution:** **13%** of overall revenue (vs. 11% YoY) ## B. Focus Specialties & Strategy * **High-Acuity Dominance:** Robust revenue growth in focus specialties is underpinned by significant volume surges in advanced surgical and therapeutic procedures. * **Strategic Moat:** Core focus remains on **tertiary, quaternary, and critical care**, providing a defensive hedge against the rise of online primary care platforms. * **Mental Health Expansion:** Diversified into specialized mental health care via the launch of **Adayu**, a **36-bed** dedicated facility in Gurugram. ## C. Technology & Clinical Innovation * **ARPOB Drivers:** Integration of high-end technologies like **MR Linac and Gamma Knife** is actively scaling the oncology and day-care segments, improving Average Revenue Per Occupied Bed. * **Genomic Advancement:** Enhanced clinical capabilities through the **Illumina NovaSeq X platform**, enabling routine use of hereditary cancer and whole exome sequencing. * **Diagnostic Expansion:** Portfolio broadened with over **50 new specialized tests** across molecular diagnostics, oncology, and neuro-oncology. ## D. Preventive Health * **Wellness Momentum:** Increased revenue contribution from the preventive portfolio reflects successful penetration of corporate wellness and specialized preventive panels. --- # 5. M&A & Strategic Initiatives ## A. Key Figures * **Network Expansion:** **~800 beds** added via brownfield/M&A * **Asset Specifics:** **125 beds** (People Tree, Bengaluru) · **200 beds** (Greater Noida lease) · **228 beds** (Shrimann, Jalandhar) * Gleneagles Revenue: ~₹70 Cr per month current trend ## B. Recent Acquisitions & Integration * **Strategic Clustering:** The Bengaluru acquisition targets an underserved micro-market to build a competitive network cluster amid high residential growth. * **Future Scalability:** The Jalandhar acquisition includes land parcels providing a clear path to more than double capacity to **450+ beds**. * **Transaction Status:** The Gleneagles deal remains in the evaluation stage, pending a **majority of minority approval** which precludes a definitive timeline. * **Operational Focus:** Management is prioritizing the integration of new units and cost optimization to align with stated financial guidance. ## C. Digital Ecosystem * **Proprietary Growth vs. Cash Burn:** Fortis is eschewing aggressive digital expansion and third-party platforms to avoid high customer acquisition costs, favoring a gradual build-out of its own app. * **Workflow Optimization:** Recent enhancements include geospatial phlebotomist assignment and real-time loyalty tracking to improve the digital patient journey. * **Long-term Funnel:** Digital strategy is designed to capture the patient transition from preventative/primary care into the company's core tertiary care services. ## D. Ownership & Capital Structure * **Parental Support:** IHH Healthcare intends to increase its stake to **50%**, with a potential **₹10,000 Cr** equity infusion to bankroll aggressive Indian market expansion. * **Diagnostic Demerger:** Management ruled out a near-term demerger of the diagnostics business, prioritizing margin improvement and operational strength before pursuing value-unlocking events. --- # 6. Pricing & Regulatory Risks ## A. Key Figures * **Oncology Drug Margin Cap:** **30%** of MRP for ECHS and CGHS business ## B. Drug Price Caps & Mitigation * **Regional Revenue Headwinds:** Regulatory price capping in medical oncology has triggered a drop in occupancy and revenue, specifically within the **North and Punjab regions**. * **Selective Admissions Policy:** To protect profitability against capped margins, the company has pivoted to advising certain patients to procure medications externally rather than providing them in-house. * **Margin Resilience:** Despite the top-line impact from recent drug price changes, the overall effect on profit margins remains contained, with management maintaining a comfortable outlook on the current profile. ## C. Government Schemes & Market Dynamics * **Portfolio Re-rating:** Fortis is currently navigating price increases across most specialties for CGHS and ECHS; however, full realization is pending **super specialty registrations** and billing clarifications. * **Strategic Diversification:** While industry-wide resolutions on government circulars remain uncertain, the company is actively pivoting toward alternate business opportunities to offset regulatory volatility. ## D. Competitive Intensity * **Supply Side Stability:** Despite new capacity entering the **Gurgaon and Noida** markets, management reports only a marginal increase in doctor costs and expects no significant attrition. * **Strategic Positioning:** The company is leveraging clinical outcomes to differentiate from PE-backed competitors, viewing the proliferation of private equity platforms as a potential future strategic opportunity. --- # 7. Guidance & Outlook ## A. Key Figures * **Hospital Revenue Growth:** **15%+** Projected for current FY · **15%+** Jaipur facility (Next FY) * **Long-term Margin Target:** **25%** by FY28 * **Facility Margins:** **13% to 14%** Jaipur facility · **18% to 20%** Mature greenfield EBITDA ## B. Revenue & Margin Trajectory * **Organic Growth Focus:** Revenue guidance for FY27 is predicated strictly on **organic operations**, excluding any upside from future M&A. * **Profitability Drivers:** Margin expansion toward the long-term target is underpinned by brownfield expansions and the full integration of prior-year acquisitions. ## C. Growth Strategy & Capital Allocation * **Strategic Commitment:** India is designated as the primary focus market for IHH, with management committed to providing capital infusions to meet all growth requirements. * **Greenfield Maturation Cycle:** New projects are expected to reach cash breakeven within **18 to 24 months**, achieving mature margin profiles approximately one year thereafter.